News
News
- Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference
05/11/2020 / 22:05 - GlobeNewswire - Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million
05/11/2020 / 12:30 - GlobeNewswire - ASLAN Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
05/11/2020 / 11:34 - GlobeNewswire - Athenex, Inc. Reports First Quarter Ended March 31, 2020 Financial Results and Provides Corporate Update
05/07/2020 / 13:00 - GlobeNewswire - Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020
04/30/2020 / 14:00 - GlobeNewswire - UPDATE - ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19
04/13/2020 / 11:17 - GlobeNewswire - ASLAN Intends to Resume Screening as Soon as Government Restrictions are Lifted and is Taking Steps to Open Sites in Australia to Accelerate Recruitment
04/13/2020 / 10:21 - GlobeNewswire - Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA• (omadacycline)
04/02/2020 / 14:00 - GlobeNewswire - Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA• (omadacycline)
04/01/2020 / 14:00 - GlobeNewswire - ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
03/18/2020 / 10:18 - GlobeNewswire
Real-time